| Home | E-Submission | Sitemap | Contact Us |  
top_img
JPTM > Volume 45(4); 2011 > Article
The Korean Journal of Pathology 2011;45(4): 379-385.
doi: https://doi.org/10.4132/KoreanJPathol.2011.45.4.379
Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach.
Dae Hyun Song, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong Hee Lee, Sang Ho Jeong, Gyung Hyuck Ko
1Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Korea. gyunghko@gnu.ac.kr
2Gyeongsang Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea.
3Department of Surgery, Gyeongsang National University School of Medicine, Jinju, Korea.
ABSTRACT
BACKGROUND: Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach. METHODS: IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas. RESULTS: IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors. CONCLUSIONS: IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.
Key Words: Stomach; Carcinoma; Adenoma; IMP3 protein